Screener
Collegium Pharmaceutical, Inc. COLL Nucynta ER — Product revenues, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Xtampza ER | 45,006 | 52,605 | 95,775 | 100,247 |
| Jornay PM | 46,058 | 32,626 | 84,951 | 61,165 |
| Nucynta IR | 14,356 | 26,501 | 40,434 | 53,918 |
| Nucynta ER | 15,723 | 19,946 | 33,957 | 39,632 |
| Azstarys | 12,910 | — | 12,910 | — |
| Symproic | 3,020 | 3,722 | 7,213 | 6,537 |
| Nucynta ER AG | 2,775 | — | 4,221 | — |
| Nucynta IR AG | 2,361 | — | 3,619 | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net?
- Collegium Pharmaceutical, Inc. (COLL) reported nucynta ER — product revenues, net of $15.72M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net decreased by 21.2% year-over-year, from $19.95M to $15.72M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net?
- Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s nucynta ER — product revenues, net has grown at a 3.4% compound annual growth rate (CAGR), from $70.94M to $80.99M.
- What does nucynta ER — product revenues, net mean?
- This metric represents the total net sales generated from the specific pharmaceutical product line after accounting for rebates, discounts, and returns. It serves as a key indicator of the product's market adoption, pricing power, and commercial performance within the company's specialty pain management portfolio. Monitoring this revenue stream helps investors assess the lifecycle stage and competitive positioning of the asset in the chronic pain treatment market.
Ask your AI about Collegium Pharmaceutical, Inc.'s nucynta er — product revenues, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude